1 not yet recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Amyloid Light Chain (AL) Amyloidosis: new trials by email Literature Review of Amyloid Light Chain (AL) Amyloidosis trials Research Report on Amyloid Light Chain (AL) Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
Amyloidosis (1) · Immunoglobulin Light-chain Amyloidosis (1)
Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Metabolic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1) · Nutritional and Metabolic Diseases (1) · Paraproteinemias (1) · Proteostasis Deficiencies (1)
Bortezomib (1) · Cyclophosphamide (1) · Dexamethasone (1) · daratumumab (1)
AbbVie (1)